Dominic Schmidt

Dominic Schmidt is an accomplished professional in the biotechnology sector, currently serving as a Board Observer at Beacon Therapeutics and a General Partner at Advent Life Sciences since April 2022, where responsibilities include investing and building biotech companies. Schmidt holds several Non-Executive Director positions at Pheno Therapeutics Ltd, AviadoBio, and Amphista Therapeutics Limited, among others, and previously served as Non-Executive Director at Purespring Therapeutics and Forcefield Therapeutics. Notably, Schmidt was a Partner at Syncona Limited from March 2014 to March 2022, contributing to its mission of developing leaders in life sciences. Academic credentials include a Ph.D. in Oncology from the University of Cambridge and a German Diplom Degree/M.Sc. in Biochemistry from Freie Universität Berlin.